Hospital visiting guidelines updated 20 July 2022: Hospital visitors must wear a surgical/medical paper mask. Fabric face coverings are no longer acceptable. See our COVID-19 pages for detailed information about hospital visiting guidelines, COVID-19 tests and care in the community advice. See www.vaccinatecanterburywestcoast.nz for information about vaccinations.
We are at ORANGE according to the NZ COVID-19 Protection Framework
Last updated:
9th April 2022
We have therefore tightened visitor restrictions for all Te Whatu Ora Waitaha Canterbury hospitals and health facilities.
Kia whakahaumaru te whānau, me ngā iwi katoa – this is to keep everybody safe:
By sticking to the rules above, you help keep our patients, staff, other visitors and yourself safe. We thank you in advance for your patience and understanding as our staff work hard to protect and care for some of the most vulnerable in our community.
Exceptions to the ‘one visitor’ policy
Visiting patients with COVID-19
You must NOT visit the hospital if you
Exceptions for people with disabilities
An exception will be made for people with disabilities who are in hospital or have to attend an outpatient appointment – where they need a support person to access health services. For example, a sign language interpreter, support person for someone with a learning disability, or someone to assist with mobility. The support person is in addition to the one permitted visitor.
Everyone visiting our facilities must wear a mask, no exceptions
While we appreciate that some people have legitimate reasons for being exempt from wearing a mask and may even have an official card to confirm this, people who cannot or will not wear a mask cannot visit someone in hospital or attend hospital, other than to access healthcare. This is another measure to minimise the risk to vulnerable patients.
Patients and visitors should also read the additional more detailed visiting guidelines for each specific hospital.
More COVID-19 information
Autoimmune lymphoproliferative syndrome (ALPS) is a human genetic disorder of lymphocyte apoptosis resulting in an accumulation of lymphocytes and childhood onset chronic lymphadenopathy, splenomegaly, multilineage cytopenias, and an increased risk of B-cell lymphoma. ALPS is caused by mutations in Fas (CD95), Fas ligand and caspase 10.
Immunology
APOP
CD95 (functional)
2 weeks
5
2
2
Laboratory MUST be contacted before sample is taken (03) 364 0413. 1 week's notice is required.
Please collect 5 mL heparinised blood from the patient AND a healthy (unrelated) adult control.
5mL (2ml paed) Heparin(Green) blood from patient+healthy ctrl
5
Ambient (8 - 24 degrees Celsius)
Send at ambient temperature to arrive within 24 h.
– Normal apoptosis
– Low apoptosis
– Absent apoptosis
This is a two stage assay. Firstly expression of surface Fas (CD95) is stimulated during culture with IL-2 and anti-CD3. Secondly apoptosis is induced using an anti-Fas antibody. Annexin V positive cells are enumerated using flow cytometry.
$369.64 (Exclusive of GST)
8781
This test measures functional Fas (CD95) activity but will not detect somatic Fas mutations, or mutations in Fas ligand (FasL).
Genetic testing for ALPS (sequencing of CD95, FasL, Casp10, Casp8, SH2D1A and promoter regions) is available at Dept of Immunology, Camelia Botnar Laboratories, Great Ormond St. Hospital (contact Kimberly Gilmour Kimberly.Gilmour@gosh.nhs.uk) although there may also be centres in Australia.
Biomarkers from serum (sFasL, Vit B12, IL-18, IL-10) may also be useful in the diagnosis of ALPS1,2. These are not currently available at CHL.
1. Oliveira et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood. 2010 Oct;116:35-40.
2. Caminha et al. Using biomarkers to predict the presence of FAS mutations in patients with features of the autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol. 2010;125:946-949.